Clinical Trials Currently Enrolling
Please contact the individual trial centers listed below for enrollment information. You may also click on the clinicaltrials.gov link for specific trial information.| Product Candidate | Location | Principal Investigator | Indication | Phase | Contact |
|---|---|---|---|---|---|
| MKC-1 clinicaltrials.gov | Princess Margaret Hospital | Dr. Karen Yee | Leukemia | I | Dr. Karen Yee 416-946-4495 |
| MKC-1 with Pemetrexed clinicaltrials.gov | Multi-Center Trial | Dr. Nasser H. Hanna | Advanced Cancer and Non-Small Cell Lung Cancer (NSCLC) | I / II | Deborah Estes, R.N. (317) 278-6599 |
| ENMD-1198 | University of Colorado Cancer Center, Aurora, CO | Dr. Ross Camidge | Advanced Cancer | I | Mary Kay Schultz (720) 848-0376 or Sharon VanDoren (720) 848-1543 |
| MKC-1 | Multi-center | Dr. Eunice Kwak | Pancreatic Cancer | II | Susan Sheehan 617-724-9347 phone / 617-724-2840 fax |
| MKC-1 | Multi-center | Dr. Amit Oza | Ovarian/Endometrial Cancers | II | Dr. Amit Oza Tel: 416-946-2818 |
| MKC-1 | University of Wisconsin | Glenn Liu, M.D. | Advanced Cancer | I | Cancer Connect (800) 622-8922 |
| ENMD-2076 | University of Colorado and Dana-Farber Cancer Institute | Dr. Wells Messersmith & Dr. Geoffrey Shaprio | Advanced Cancers | I | University of Colorado, Stacy Grolnic, RN (720) 848-0655 Dana Farber Cancer Institute, Pilar de la Rocha (617) 632-5841 |
Ongoing Trials, Enrollment Closed
| Product Candidate | Location | Principal Investigator | Indication | Phase |
|---|---|---|---|---|
| Panzem® NCD w/ Temodar® | Preston Robert Tisch Brain Tumor Center at Duke University Medical Center | Dr. Annick Desjardins | Glioblastoma Multiforme (GBM) | II |
| Panzem® NCD | Multi-Center Trial | Dr. Glenn Liu | Renal Cell Carcinoma | II |
| Panzem® NCD | Multi-Center Trial | Dr. Glenn Liu | Hormone-Refractory Prostate Cancer | II |
| MKC-1 | Multi-Center Trial | Advanced and Metastatic Breast Cancer | II | |
| Panzem® NCD | Duke University Medical Center | Dr. Kimberly L. Blackwell | Metastatic Breast Cancer | Ib |
| Panzem® NCD | Indiana University Cancer Center, Indianapolis, IN | Dr. Christopher J. Sweeney | Advanced Cancer | Ib (Part B) |
| Panzem® NCD | Dana-Farber Cancer Institute, Boston, Massachusetts | Dr. Matthew Kulke | Carcinoid Cancer | II |
| Panzem® NCD | Multi-Center Trial | Dr. Daniela E. Matei | Ovarian Cancer | II |
| Panzem® NCD | Brain Tumor Center at Duke University Medical Center, Durham, NC | Dr. David A. Reardon | Brain Cancer | II |
| Panzem® Capsules | Mayo Clinic, Rochester, MN | Dr. Vincent Rajkumar | Multiple Myeloma | II |
| Panzem® Capsules | Dana-Farber Cancer Institute, Boston, MA | Dr. Paul Richardson | Multiple Myeloma | II |
Completed Trials
| Product Candidate | Location | Principal Investigator | Indication | Phase |
|---|---|---|---|---|
| Panzem® NCD | University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WI | Dr. George Wilding | Advanced Cancer | Ib (Part B) |
| Panzem® NCD | University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WI | Dr. George Wilding | Advanced Cancer | Ib (Part A) |
| Panzem® NCD | Indiana University Cancer Center, Indianapolis, IN | Dr. Christopher J. Sweeney | Advanced Cancer | Ib (Part A) |
| Panzem® Capsules * | National Cancer Institute, Bethesda, MD | Dr. William D. Figg, Dr. William Dahut | Advanced Solid Tumors | I |
| Panzem® Capsules ** | Mayo Clinic, Rochester, MN | Dr. Charles Erlichman | Advanced Solid Tumors | I |
| Panzem® Capsules | University of Wisconsin, Madison, WI | Dr. George Wilding | Prostate Cancer | II |
| Panzem® Capsules | Indiana University Cancer Center, Indianapolis, IN | Dr. Chris Sweeney, Dr. George Sledge | Prostate Cancer | II |
| Panzem® Capsules | Indiana University Cancer Center, Indianapolis, IN | Dr. Kathy Miller , Dr. George Sledge | Metastatic Breast Cancer | I |
| Panzem® Capsules w/ Taxotere® | Indiana University Cancer Center, Indianapolis, IN | Dr. Kathy Miller , Dr. George Sledge | Metastatic Breast Cancer | I |
** NCI-sponsored trial. EntreMed provided only the study drug for this trial.
